New drug could get heart surgery patients home days earlier
NCT ID NCT07357675
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether a drug called EA-230 can help people recover faster after coronary artery bypass surgery. About 300 adults scheduled for elective bypass surgery will receive either EA-230 or a placebo during the operation. Researchers will measure how long participants stay in the ICU and hospital, and whether they have fewer complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EA-230 (a drug given intravenously during surgery)
What this could lead to
If it works, EA-230 could help people recover faster after bypass surgery, spending less time in the ICU and hospital with fewer serious complications.
What could go wrong
This is an early Phase 3 trial, so results are not yet proven. The drug may not work as well in a larger group, and there is always a risk of side effects not seen in earlier studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE (CAD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MAYO clinic
Rochester, Minnesota, 55905, United States
-
Medisch Spectrum Twente
Enschede, Netherlands
-
RadboudUMC
Nijmegen, Netherlands
-
St Thomas' Hospital
London, United Kingdom
-
UZ Gent
Ghent, Belgium